<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200516047462N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-05-17</date_registration>
      <primary_sponsor>Kashan University of Medical Sciences</primary_sponsor>
      <public_title>Intervention</public_title>
      <acronym></acronym>
      <scientific_title>The effect of methanolic extract of hyoscyamus niger containing steroidal glycosides with propolis in patients with acute respiratory infection (infection or suspected covid-19): A clinical trials</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-05-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/48141</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: After acceptance and registration, these samples are entered in study by physician and nurse of clinic and also project manager based on the entry and exit criteria. The samples are divided into two groups by method of terminated block randomization with blocks 4 and 6. Prescriptive drugs (intervention and placebo) are determined based on this method with a special number to them. Physician and patient are not aware of intervention type and the patient's assignment to each treatment will be assign randomly, Blinding description: Physician and patient are unaware of drug or placebo receiving and there are codes that were registered on syrup and only the epidemiologist informs as a plan executor.</study_design>
      <phase>N/A</phase>
      <hc_freetext>covid 19.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Products containing 10 mg of methanolic extract plus 450 mg of propolis will be prescribed three times a day for each patient. This amount of active ingredients is dissolved in 30cc of simple BP syrup. This 30 cc is ordered in 10cc (one tablespoon) every 8. The time will be prescribed. The formulated syrup will be given to the patients in the amount of 60 cc required by the above-mentioned order for 2 days and the patients will go to the clinic every two days after receiving the medicine again, the questionnaire and clinical symptoms will be referred to the clinic. In addition, suspected patients with covid 19 will be delivered to patients after the approval of an infectious disease specialist and, if the patient agrees, and will receive a signature and fingerprint in the syrup consent form. Prescribing syrup and examining the patient's symptoms are 6 days. Intervention 2: Control group: Simple BP syrup (without therapeutic products) will be prescribed every 10 hours with a 10cc (one tablespoon) recipe. Two days later, the drug will be returned to the clinic, a questionnaire and clinical signs will be sent to the clinic. In addition, suspected patients with covid 19 will be delivered to patients after the approval of an infectious disease specialist and, if the patient agrees, and will receive a signature and fingerprint in the syrup consent form. Prescribing syrup and examining the patient's symptoms are 6 days.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Due to the completion of the second drug research</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Morteza Kosari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 16, Hakim Alley. , Montazeri St. , Badrod Town</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8766113894</zip>
        <telephone>+98 31 5434 6622</telephone>
        <email>kosarimorteza12@gmail.com</email>
        <affiliation>Kashan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Morteza Kosari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 16, Hakim Alley.,  Montazeri St. , Badrod Town</address>
        <city>Badrod</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8766113894</zip>
        <telephone>+98 31 5434 6622</telephone>
        <email>kosarimorteza12@gmail.com</email>
        <affiliation>Kashan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>The patient must have a voluntary consent to participate in operation; The patient's clinical symptoms such as: dry cough, shortness of breath, fever, shortness of breath, fatigue, etc. in suspected or associated with COVID-19 is evaluated after treatment and these symptoms are compared with placebo group.</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Heart patients, mental patients and pregnant women</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>U07.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Covid-19</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Products containing 10 mg of methanolic extract plus 450 mg of propolis will be prescribed three times a day for each patient. This amount of active ingredients is dissolved in 30cc of simple BP syrup. This 30 cc is ordered in 10cc (one tablespoon) every 8. The time will be prescribed. The formulated syrup will be given to the patients in the amount of 60 cc required by the above-mentioned order for 2 days and the patients will go to the clinic every two days after receiving the medicine again, the questionnaire and clinical symptoms will be referred to the clinic. In addition, suspected patients with covid 19 will be delivered to patients after the approval of an infectious disease specialist and, if the patient agrees, and will receive a signature and fingerprint in the syrup consent form. Prescribing syrup and examining the patient's symptoms are 6 days.</i_keyword>
      <i_keyword>Control group: Simple BP syrup (without therapeutic products) will be prescribed every 10 hours with a 10cc (one tablespoon) recipe. Two days later, the drug will be returned to the clinic, a questionnaire and clinical signs will be sent to the clinic. In addition, suspected patients with covid 19 will be delivered to patients after the approval of an infectious disease specialist and, if the patient agrees, and will receive a signature and fingerprint in the syrup consent form. Prescribing syrup and examining the patient's symptoms are 6 days.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Shortness of breath, medicine, dry cough, chills and etc. Timepoint: May and June. Method of measurement: Quantitative and qualitative.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kashan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-05-06</approval_date>
        <contact_name>Ethics committee of Kashan University of Medical Sciences</contact_name>
        <contact_address>Ghotb Ravandi Blvd Kashan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
